Case: Patents/Obviousness (P.T.A.B.)

The Patent Trial and Appeal Board said that challenged claims of Ravgen Inc.'s patent that relates to noninvasive methods for sampling DNA and detection of genetic disorders in a fetus aren’t unpatentable as obvious over prior art, in an inter partes review by Labcorp. of America Holdings. According to the board, the challenged claims aren‘t obvious over various combinations of prior art, including prior art that relates to a study on the effects of blood-processing protocols on the quantification of cell-free fetal and total DNA in maternal plasma, and that discloses methods for labeling intracytoplasmic target molecules in order to ...